Archive for the 'Ingredients' Category

Let’s Fight Adulteration with Information

Erik Greb PharmTech editorEconomically motivated adulteration became a major concern after heparin manufactured by Baxter Healthcare was contaminated with oversulfated chondroitin sulfate. FDA told the Government Accountability Office (GAO) that getting information from industry about potential instances of economic adulteration is crucial to addressing the problem. Companies have been reluctant to share this information, but a GAO report suggests a possible solution. Read more »

Building Relationships at CPhI

Patricia Van Arnum PharmTech editor In attending CPhI this week in Frankfurt, one theme that repeatedly emerged was the increasing importance of CROs, CDMOs, and CMOs to build more strategic, deeper, and collaborative relationships with pharmaceutical companies as a way to meet the evolving needs of the industry and as a a mutual tool in value creation. Read more »

Changing Times for Pharma Chemical Outsourcing

Patricia Van Arnum PharmTech editor The Pharma ChemOutsourcing conference, an annual event that brings together pharmaceutical companies, CROs, and CMOs to discuss industry trends and perspectives, was held in Long Branch, New Jersey, last week. The central question at the heart of many of the discussions was a fundamental but important one: where is the opportunity in pharmaceutical outsourcing, specifically in pharmaceutical chemical development and manufacturing? Read more »

Let’s Be Friends In Regulation

Stephanie Sutton Pharm Tech EuropeThere’s a lot of activity between the EMA and the FDA at the moment. Recently, reports have been published following two international pilot programmes regarding API inspections and good clinical practices (GCP). The outcome of the pilots? Success! Read more »

An Upward Trajectory for New Drug Approvals

Patricia Van Arnum PharmTech editor Good news on the drug-approval front. Through the end of July, FDA’s Center for Drug Evaluation and Research had approved 21 new drugs (new molecular entities and new biologics license applications), which equals the total number of new drugs approved in all of 2010. Although not enough to claim a reversal of the recent downward trend in drug R&D productivity, the numbers are a good sign for the industry. Read more »

QbD in Theory and Practice

Erik Greb PharmTech editorThe pharmaceutical industry has sometimes been slow to embrace ideas that promise great practical benefits. The industry’s ingrained aversion to risk is partly to blame, but it’s usually not the whole story. Take the quality-by-design (QbD) initiative, which posits that the better a company understands a product’s quality attributes, the more likely that product will be safe and efficacious. The industry has generally supported this initiative, and Pfizer has brought it into the spotlight. Read more »

Drug Shortages Rise, but No Requirement to Report Them

Angie Drakulich PharmTech editorIn 2008, a shortage of pig intestines, used in the manufacture of the blood anticoagulant heparin, was associated with the drug product’s contamination in China and led to many deaths around the globe. This event demonstrated the significance of a shortage of supplies needed to manufacture a particular drug and its effect on public health. Read more »

Live from ExcipientFest and IPEC: Atypical Actives, Coprocessed Excipients, Functionality, and More

Angie Drakulich PharmTech editorIf you’re not in Baltimore this week, you’re missing out on a lot of great educational information regarding the use of excipients in the pharma industry. ExcipientFest in partnership with IPEC is hosting its annual conference and exhibition. The entertainment for participants, including a reception on the USS Constellation naval  ship in the Inner Harbor, has also been quite an experience.  Read more »

Informex 2011: Tracking the Fortunes of Chemically Synthesized APIs

Patricia Van Arnum PharmTech editor I am here in Charlotte, North Carolina, this week for Informex 2011, the trade show of custom and batch manufacturers, which raises a fundamental question. What is the future for outsourcing of chemically synthesized active pharmaceutical ingredients (APIs) and pharma intermediates? Read more »

Potential Contamination in Crospovidone

Angie Drakulich PharmTech editorFDA issued an alert today that it has detected “excessive levels of peroxide in one lot of Crospovidone (cross linked polyvinyl N-pyrrolidone) manufactured by China-based Tianjin Boai NKY International Ltd.” Although there have not been any related adverse-event reports to date and although the level of peroxide found does not pose a major health risk, said the agency in an advisory statement yesterday, there is concern that elevated levels of peroxide can cause “subpotent finished products.” Read more »

« Previous PageNext Page »